Conba announced on October 8 that its wholly-owned subsidiary Hangzhou Conba has received the Drug Registration Certificate from the National Medical Products Administration for two strengths of dapoxetine hydrochloride tablets. The drug is available in 30 mg and 60 mg strengths, classified as a Category 4 chemical drug, and is a short-acting selective serotonin reuptake inhibitor indicated for the treatment of premature ejaculation in men aged 18 to 64. To date, Hangzhou Conba has invested 9.063 million yuan in research and development for this drug. According to data from Menet, sales of dapoxetine hydrochloride tablets in China's corresponding medical and retail terminal markets totaled 1.027 billion yuan in 2025. In the first half of 2026, Conba achieved revenue of 3.701 billion yuan and net profit attributable to the parent company of 378 million yuan.
Zhejiang CONBA Pharmaceutical Co LtdWholly-owned subsidiary Hangzhou Conba received the Drug Registration Certificate for dapoxetine hydrochloride tablets, adding a new approved product.
